# Targeting neoantigens for cancer immunotherapy

Review · Xuan Zhao, Xiaoxin Pan, Yi Wang, Yi Zhang

- Archive id: doi:10.1186/s40364-021-00315-7
- Published: 2021-07-28
- Venue: Biomarker Research
- DOI: https://doi.org/10.1186/s40364-021-00315-7
- PMID: 34321091
- Citations: 78
- Source URL: https://doi.org/10.1186/s40364-021-00315-7
- PDF: https://biomarkerres.biomedcentral.com/counter/pdf/10.1186/s40364-021-00315-7
- Provenance: openalex

## Abstract

Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generation sequencing and utilization of machine-learning algorithms, it has become feasible to computationally predict neoantigens by depicting genetic alterations, aberrant post-transcriptional mRNA processing and abnormal mRNA translation events within tumor tissues. Consequently, neoantigen-based therapies such as cancer vaccines have been widely tested in clinical trials and have demonstrated promising safety and efficacy, opening a new era for cancer immunotherapy. We systematically summarize recent advances in the identification of both personalized and public neoantigens, neoantigen formulations and neoantigen-based clinical trials in this review. Moreover, we discuss future techniques and strategies for neoantigen-based cancer treatment either as a monotherapy or as a combination therapy with radiotherapy, chemotherapy or immune checkpoint inhibitors.

_Abstract reproduced under CC-BY (publisher license, via OpenAlex)._

Topics: [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.